Version 1
: Received: 17 October 2024 / Approved: 18 October 2024 / Online: 21 October 2024 (08:34:15 CEST)
How to cite:
Mayasin, Y. P.; Osinnikova, M. N.; Kharisova, C. B.; Kitaeva, K. V.; Filin, I. Y.; Gorodilova, A. V.; Kutovoi, G. I.; Solovyeva, V. V.; Golubev, A. I.; Rizvanov, A. A. Extracellular Matrix as a Target in Melanoma Therapy: From Hypothesis to Clinical Trials. Preprints2024, 2024101515. https://doi.org/10.20944/preprints202410.1515.v1
Mayasin, Y. P.; Osinnikova, M. N.; Kharisova, C. B.; Kitaeva, K. V.; Filin, I. Y.; Gorodilova, A. V.; Kutovoi, G. I.; Solovyeva, V. V.; Golubev, A. I.; Rizvanov, A. A. Extracellular Matrix as a Target in Melanoma Therapy: From Hypothesis to Clinical Trials. Preprints 2024, 2024101515. https://doi.org/10.20944/preprints202410.1515.v1
Mayasin, Y. P.; Osinnikova, M. N.; Kharisova, C. B.; Kitaeva, K. V.; Filin, I. Y.; Gorodilova, A. V.; Kutovoi, G. I.; Solovyeva, V. V.; Golubev, A. I.; Rizvanov, A. A. Extracellular Matrix as a Target in Melanoma Therapy: From Hypothesis to Clinical Trials. Preprints2024, 2024101515. https://doi.org/10.20944/preprints202410.1515.v1
APA Style
Mayasin, Y. P., Osinnikova, M. N., Kharisova, C. B., Kitaeva, K. V., Filin, I. Y., Gorodilova, A. V., Kutovoi, G. I., Solovyeva, V. V., Golubev, A. I., & Rizvanov, A. A. (2024). Extracellular Matrix as a Target in Melanoma Therapy: From Hypothesis to Clinical Trials. Preprints. https://doi.org/10.20944/preprints202410.1515.v1
Chicago/Turabian Style
Mayasin, Y. P., Anatolii I. Golubev and Albert A. Rizvanov. 2024 "Extracellular Matrix as a Target in Melanoma Therapy: From Hypothesis to Clinical Trials" Preprints. https://doi.org/10.20944/preprints202410.1515.v1
Abstract
Melanoma is a malignant, highly metastatic neoplasm showing increasing morbidity and mortality. Tumor invasion and angiogenesis are based on remodeling of the extracellular matrix (ECM). Selective inhibition of functional components of cell-ECM interaction, such as hyaluronic acid (HA), matrix metalloproteinases (MMPs), and integrins, may inhibit tumor progression and enhance the efficacy of combination treatment with checkpoint inhibitors (ICBs), chemotherapy, or immunotherapy. In this review, we have combined the results of different approaches targeting extracellular matrix elements in melanoma in preclinical and clinical studies. The identified limitations of many approaches, including side effects, low selectivity and toxicity, indicate the need for further studies to optimize therapy. Nevertheless, significant progress in expanding our understanding of tumor biology and the development of targeted therapies holds great promise for the early approaches developed several decades ago to inhibit metastasis through ECM targeting.
Biology and Life Sciences, Biochemistry and Molecular Biology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.